Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry has validated previous findings of elevated lung tissue amino acid levels in idiopathic pulmonary fibrosis (IPF), claims a new study, suggesting that online breath analysis can be a practical tool for rapid screening for IPF.
Patients with sporadic idiopathic pulmonary fibrosis (IPF) aged <60 years and who have nonspecific immunological or haematological abnormalities are at increased risk of telomere shortening, as well as present a poorer prognosis, according to a study.
INPULSIS-ON*, the open-label extension of the phase III INPULSIS trials, demonstrated the safety of nintedanib over a long-term period of treatment in patients with idiopathic pulmonary fibrosis (IPF).
There have been a substantial number of severe adverse events (SAE) and a faster decrease in forced vital capacity (FVC) in patients with possible idiopathic pulmonary fibrosis (posIPF) taking steroid therapy, a new study has shown.
Patients with combined pulmonary fibrosis and emphysema (CPFE) are likely to develop pulmonary hypertension, and this likelihood may be explained by the summed extents of interstitial lung disease (ILD) and emphysema, according to a study.
Treatment with glucocorticoid appears to be associated with an accelerated decline in forced vital capacity and a substantial number of serious adverse events among patients with possible idiopathic pulmonary fibrosis (IPF), according to a study.
Being diagnosed or treated for gastro-oesophageal reflux disease (GORD) has little impact on the survival outcomes of patients with idiopathic pulmonary fibrosis (IPF), according to a study presented as a poster at APSR 2017.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.